1887

Abstract

Semliki Forest virus (SFV) infection of mice was used as a model to study the applicability of synthetic peptides containing only linear epitopes as viral vaccines. The identification of linear epitopes with vaccine potential on the E2 membrane protein of SFV was based on the binding of SFV-specific antibodies to a set of overlapping synthetic hexapeptides (Pepscan) representing the whole E2 amino acid sequence. The 14 available E2-specific monoclonal antibodies which were protective proved to be unsuitable for the identification of linear epitopes because they recognized only conformational epitopes, as indicated by their lack of reactivity with unfolded, reduced E2 protein on immunoblots. Three epitopes were detected with polyclonal anti-SFV serum at amino acid positions 135 to 141, 177 to 185 and 240 to 246 of the E2 protein. Synthetic peptides containing these epitopes were coupled to a carrier protein and tested as a vaccine. Mice immunized with the peptide containing amino acids 240 to 255 of protein E2 were protected against a challenge with virulent SFV but protection of mice immunized with the peptides containing amino acids 126 to 141 or 178 to 186 was only marginally better than that of controls. The prechallenge sera of most peptide-immunized mice reacted with SFV-infected cells but none of these sera neutralized the virus . However, protection of mice correlated well with SFV-specific antibody titre, suggesting antibody-mediated protection.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-72-3-557
1991-03-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/72/3/JV0720030557.html?itemId=/content/journal/jgv/10.1099/0022-1317-72-3-557&mimeType=html&fmt=ahah

References

  1. Anderer F. A., Schlumberger H. D. 1965; Properties of different artificial antigens immunologically related to tobacco mosaic virus. Biochimica et biophysica acta 97:503–509
    [Google Scholar]
  2. Ariel N., Lehrer S., Elhanaty E., Sabo T., Brodt P., Lachmi B., Katz D., Levin R., Grosfeld H., Velan B., Shafferman A. 1990; Serologically defined linear epitopes in the E2 envelope glycoprotein of Semliki Forest virus. Archives of Virology 113:99–106
    [Google Scholar]
  3. Arnon R. 1972; Synthetic vaccines - dream or reality. In Immunity of Viral and Rickettsial Diseases pp 209–222 Edited by Kohn A., Klinkenberg A. M. New York: Plenum Press;
    [Google Scholar]
  4. Barany G., Merrifield R. B. 1980; Solid–phase peptide synthesis. In The Peptides vol 1 pp 1–284 Edited by Gross E., Meienhofer J. New York: Academic Press;
    [Google Scholar]
  5. Bayer H., Hunsmann G. 1987; Synthetic vaccines against Friend murine leukaemia virus–induced erythroleukaemia: in vivo and in vitro studies with synthetic oligopeptides and sequence-specific antisera. Journal of General Virology 68:515–522
    [Google Scholar]
  6. Benjamin D. C., Berzofsky J. A., East I. J., Gurd F. R. N., Hannum C., Leach S. J., Margoliash E., Michael J. G., Miller A., Prager E. M., Reichlin M., Sercarz E. E., SmithGill S. J., Todd P. E., Wilson A. C. 1984; The antigenic structure of proteins: a reappraisal. Annual Review of Immunology 2:67–101
    [Google Scholar]
  7. Bittle J. L., Houghten R. A., Alexander J., Shinnick T. M., Sutcliffe J. G., Lerner R. A., Rowlands D. J., Brown F. 1982; Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature, London 298:30–33
    [Google Scholar]
  8. Boere W. A. M., Benaissa-Trouw B. J., Harmsen M., Kraaijeveld C. A., Snippe H. 1983; Neutralizing and non-neutralizing monoclonal antibodies to the E2 glycoprotein of Semliki Forest virus can protect mice from lethal encephalitis. Journal of General Virology 64:1405–1408
    [Google Scholar]
  9. Boere W. A. M., Vinje J., Benaissa-Trouw B. J., Kraaijeveld C. A., Snippe H. 1984; Identification of distinct antigenic determinants on Semliki Forest virus by using monoclonal antibodies with different antiviral activities. Journal of Virology 52:575–582
    [Google Scholar]
  10. Boere W. A. M., Benaissa-Trouw B. J., Harmsen M., Erich T., Kraaijeveld C. A., Snippe H. 1985; Mechanisms of monoclonal antibody-mediated protection against virulent Semliki Forest virus. Journal of Virology 54:546–551
    [Google Scholar]
  11. Boere W. A. M., Harmsen M., Kraaijeveld C. A., Snippe H. 1986; Antigenic differences between virulent and avirulent strains of Semliki Forest virus detected with monoclonal antibodies. Archives of Virology 88:105–112
    [Google Scholar]
  12. Bradish C. J., Allner K., Maber H. B. 1971; The virulence of original and derived strains of Semliki Forest virus for mice, guineapigs and rabbits. Journal of General Virology 12:141–160
    [Google Scholar]
  13. Chanh T. C., Dreesmann G. R., Kanda P., Linette G. P., Sparrow J. T., Ho D. D., Kennedy R. C. 1986; Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO Journal 5:3065–3071
    [Google Scholar]
  14. Dalgarno L., Rice C. M., Strauss J. H. 1983; Ross River virus 26S RNA: complete nucleotide sequence and deduced sequence of the encoded structural proteins. Virology 129:170–187
    [Google Scholar]
  15. Dimarchi R., Brooke G., Gale C., Cracknell V., Doel T., Mowat N. 1986; Protection of cattle against foot-and-mouth disease by a synthetic peptide. Science 232:639–641
    [Google Scholar]
  16. Eisenberg R. J., Cerini C. P., Heilman C. J., Joseph A. D., Dietzschold B., Golub E., Long D., Ponce De Leon M., Cohen G. H. 1985; Synthetic glycoprotein D-related peptides protect mice against herpes simplex virus challenge. Journal of Virology 56:1014–1017
    [Google Scholar]
  17. Emini E. A., Jameson B. A., Wimmer E. 1984; Identification of a new neutralization antigenic site on poliovirus coat protein VP2. Journal of Virology 52:719–721
    [Google Scholar]
  18. Francis M. J., Hastings G. Z., Sangar D. V., Clark R. P., Syred A., Clarke B. E., Rowlands D. J., Brown F. 1987; A synthetic peptide which elicits neutralizing antibody against human rhinovirus type 2. Journal of General Virology 68:2687–2691
    [Google Scholar]
  19. Garoff H., Frischauf A.-M., Simons K., Lehrach H., Delius H. 1980; Nucleotide sequence of cDNA coding for Semliki Forest virus membrane glycoproteins. Nature, London 288:236–241
    [Google Scholar]
  20. Geysen H. M., Meloen R. H., Barteling S. J. 1984; Peptide synthesis used to probe viral antigens for epitopes to a resolution of a single amino acid. Proceedings of the National Academy of Sciences, U.S.A 81:3998–4002
    [Google Scholar]
  21. Geysen H. M., Barteling S. J., Meloen R. H. 1985; Small peptides induce antibodies with a sequence and structural requirement for binding antigen comparable to antibodies raised against the native protein. Proceedings of the National Academy of Sciences, U.S.A 82:178–182
    [Google Scholar]
  22. Greiser-Wilke I., Moennig V., Kaaden O.-R., Figueiredo L. T. M. 1989; Most alpha viruses share a conserved epitopic region on their nucleocapsid protein. Journal of General Virology 70:743–748
    [Google Scholar]
  23. Grosfeld H., Velan B., Leitner M., Cohen S., Lustig S., Lachmi B.-E., Shafferman A. 1989; Semliki Forest virus E2 envelope epitopes induce a nonneutralizing humoral response which protects mice against lethal challenge. Journal of Virology 63:3416–3422
    [Google Scholar]
  24. Henderson B. E., Metselaar D., Kirya G. B., Timms G. L. 1970; Investigations into yellow fever virus and other arboviruses in the northern regions of Kenya. Bulletin of the World Health Organization 42:787–795
    [Google Scholar]
  25. Ho D. D., Kaplan J. C., Rackauskas I. E., Gurney M. E. 1988; Second conserved domain of gpl20 is important for HIV infectivity and antibody neutralization. Science 239:1021–1023
    [Google Scholar]
  26. Itoh Y., Takai E., Ohnuma H., Kitajima K., Tsuda F., Machida A., Mishiro S., Nakamura T., Miyakawa Y., Mayumi M. 1986; A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees. Proceedings of the National Academy of Sciences, U.S.A. 83:9174–9178
    [Google Scholar]
  27. Jemmerson R. 1987; Antigenicity and native structure of globular proteins: low frequency of peptide reactive antibodies. Proceedings of the National Academy of Sciences, U.S.A. 84:9180–9184
    [Google Scholar]
  28. Kraaijeveld C. A., Harmsen M., Khader Boutahar-Trouw B. 1979; Cellular immunity against Semliki Forest virus in mice. Infection and Immunity 23:213–218
    [Google Scholar]
  29. Lee A. C. J., Powell J. E., Tregear G. W., Niall H. D., Stevens V. C. 1980; A method for preparing β-hCG COOH peptide-carrier conjugates of predictable composition. Molecular Immunology 17:749–756
    [Google Scholar]
  30. Lerner R. A. 1982; Tapping the immunological repertoire to produce antibodies of predetermined specificity. Nature, London 299:592–596
    [Google Scholar]
  31. McCray J., Werner G. 1987; Different rhinovirus serotypes neutralized by antipeptide antibodies. Nature, London 329:736–738
    [Google Scholar]
  32. Müller G. M., Shapira M., Arnon R. 1982; Anti-influenza response achieved by immunization with a synthetic conjugate. Proceedings of the National Academy of Sciences, U. S. A 79:569–573
    [Google Scholar]
  33. Neurath A. R., Kent S. B. H., Parker K., Prince A. M., Strick N., Brotman B., Sproul P. 1986; Antibodies to a synthetic peptide from the pre-S 120-145 region of the hepatitis B virus envelope are virus-neutralizing. Vaccine 4:35–37
    [Google Scholar]
  34. Pfaff E., Mussgay M., Böhm H. O., Schulz G. E., Schaller H. 1982; Antibodies against a preselected peptide recognize and neutralize foot-and-mouth disease virus. EMBO Journal 1:865–874
    [Google Scholar]
  35. Roehrig J. T., Gorski D., Schlesinger M. J. 1982; Properties of monoclonal antibodies directed against the glycoproteins of Sindbis virus. Journal of General Virology 59:421–425
    [Google Scholar]
  36. Snijders A., Benaissa-Trouw B. J., Oosting J. D., Snippe H., Kraaijeveld C. A. 1989; Identification of a DTH-inducing T-cell epitope on the E2 membrane protein of Semliki Forest virus. Cellular Immunology 123:23–35
    [Google Scholar]
  37. Stanley J., Cooper S. J., Griffin D. E. 1985; Alphavirus neurovirulence: monoclonal antibodies discriminating wild-type from neuroadapted Sindbis virus. Journal of Virology 56:110–119
    [Google Scholar]
  38. Talbot P. J., Dionne G., Lacroix M. 1988; Vaccination against lethal coronavirus-induced encephalitis with a synthetic decapeptide homologous to a domain in the predicted peplomer stalk. Journal of Virology 62:3032–3036
    [Google Scholar]
  39. Thornton G. B., Milich D., Chisari F., Mitamura K., Kent S. B., Neurath R., Purcell R., Gerin J. 1987; Immune responses in primates to the pre-S2 region of hepatitis B surface antigen: identification of a protective determinant. In Vaccines 87 pp 77–80 Edited by Chanock M. R., Lerner R. A., Brown F., Ginsberg H. New York: Cold Spring Harbor Laboratory;
    [Google Scholar]
  40. Vogel R. H., Provencher S. W., von Bonsdorff C.-H., Adrian A., Dubochet J. 1986; Envelope structure of Semliki Forest virus reconstructed from cryo-electron micrographs. Nature, London 320:533–535
    [Google Scholar]
  41. Weijer W. J., Drijfhout J. W., Geerlings H. J., Bloemhoff , Feijlbrief W. M., Bos C. A., Hoogerhout P., Kerling K. E. T., Popken-Boer T., Slopsema K., Wilterdink J. B., Welling G. W., Welling-Wester S. 1988; Antibodies against synthetic peptides of herpes simplex virus type 1 glycoprotein D and their capability to neutralize viral infectivity in vitro . Journal of Virology 62:501–510
    [Google Scholar]
  42. Wust C. J., Wolcott Nicholas J. A., Fredin D., Dodd D. C., Brideau R. J., Levely M. E., Brown A. 1989; Monoclonal antibodies that cross-react with the El glycoprotein of different alphavirus serogroups: characterization including passive protection in vivo . Virus Research 13101–112
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-72-3-557
Loading
/content/journal/jgv/10.1099/0022-1317-72-3-557
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error